Related Experiment Video
Updated: Jan 16, 2026

Intravitreal Injections in the Ovine Eye
Published on: July 5, 2022
Uveitis associated with immunotherapy and its response to monotherapy with difluprednate: A case report
C M Ortega1, A T Pérez Bello1, B F Graizman Kohan1
1Centro de Ojos Lomas, Lomas de Zamora, Provincia de Buenos Aires, Argentina.
Nivolumab and ipilimumab are immune checkpoint inhibitors widely used for the treatment of metastatic melanoma. They can cause various adverse effects in a significant percentage of treated patients, including uveitis. Symptoms include decreased visual acuity, pain, redness, and photophobia, which typically resolve with appropriate anti-inflammatory therapy. The aim of this work is to report a case of uveitis in a patient on ipilimumab and nivolumab for the treatment of metastatic melanoma, as well as the response to therapy with difluprednate.
Nivolumab and ipilimumab are immune checkpoint inhibitors widely used for the treatment of metastatic melanoma. They can cause various adverse effects in a significant percentage of treated patients, including uveitis. Symptoms include decreased visual acuity, pain, redness, and photophobia, which typically resolve with appropriate anti-inflammatory therapy. The aim of this work is to report a case of uveitis in a patient on ipilimumab and nivolumab for the treatment of metastatic melanoma, as well as the response to therapy with difluprednate.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

